Founded with a mission to combat therapy-resistant prostate cancer, Sisu Pharma is dedicated to developing innovative, targeted drugs using proprietary technology. Their core focus is on exploiting cellular stress mechanisms by targeting the transcription factor Heat Shock Factor 1 (HSF1), a central regulator of the heat shock response. Sisu Pharma's flagship platform, HI-LiTe, delivers selective HSF1 degraders, showing promising efficacy in cancer models where existing treatments have failed. The company aims to address the unmet medical needs in oncology, particularly for patients with limited treatment options.

Sisu Pharma has garnered attention for its pioneering approach and potential impact on cancer treatment. The company boasts a team of experts in oncology and drug development, supported by notable investors committed to advancing cancer therapeutics. Key achievements include the development of first-in-class compounds that demonstrate significant efficacy in preclinical models of therapy-resistant cancers. Sisu Pharma's work represents a significant step forward in the fight against prostate cancer, offering hope for more effective treatments and improved patient outcomes.